Dr. Reddy's launches Hepatitis E vaccine Hevaxin in India
Dr. Reddy's Laboratories launched Hevaxin, India's first approved Hepatitis E vaccine for adults aged 18-65 years, following DCGI approval. Clinical studies show the novel recombinant vaccine provides long-lasting immunity with favourable safety profiles. The launch addresses critical healthcare needs as Hepatitis E affects 20 million people globally annually, with high mortality risks for vulnerable populations. Dr. Reddy's partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for distribution, supporting India's National Viral Hepatitis Control Programme.
*this image is generated using AI for illustrative purposes only.
Dr. Reddy's Laboratories has announced the launch of Hevaxin, a groundbreaking recombinant vaccine designed to prevent Hepatitis E virus infection in India. This launch represents a significant milestone in addressing critical healthcare needs within the country's preventive medicine landscape.
Regulatory Approval and Clinical Profile
Hevaxin holds the distinction of being the only vaccine approved by the Drug Controller General of India for active immunisation against Hepatitis E in adults aged 18 to 65 years. The vaccine's development involved comprehensive clinical studies that demonstrated its effectiveness in providing protection with long-lasting immunity.
| Parameter: | Details |
|---|---|
| Target Age Group: | Adults 18-65 years |
| Regulatory Status: | DCGI approved |
| Vaccine Type: | Novel recombinant vaccine |
| Safety Profile: | Favourable safety and tolerability |
Clinical research has established that Hevaxin maintains a favourable safety and tolerability profile, making it suitable for widespread immunisation programmes across the target demographic.
Addressing Critical Healthcare Needs
Hepatitis E represents a major health concern, particularly within India, where the virus accounts for a significant share of acute hepatitis and acute liver failure cases. The disease poses substantial risks to public health infrastructure and patient outcomes.
According to World Health Organization data, the Hepatitis E virus infects nearly 20 million people globally every year. The infection carries high mortality risks among vulnerable populations, including:
- Women of childbearing age
- Patients with chronic liver disease
- Individuals with weakened immunity
Strategic Partnerships and Distribution
Dr. Reddy's has established strategic partnerships to ensure effective market penetration and distribution of Hevaxin across India. The company has collaborated with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for marketing and distribution activities.
| Partnership Aspect: | Details |
|---|---|
| Marketing Partner: | Shenzhen Mellow Hope Pharm |
| Distribution Partner: | Urihk Pharmaceutical |
| Geographic Focus: | India |
| Programme Alignment: | National Viral Hepatitis Control Programme |
The launch supports India's National Viral Hepatitis Control Programme and addresses a critical unmet need in preventive healthcare infrastructure.
Market Performance
Shares of Dr. Reddy's Laboratories were trading at ₹1,245.20, down 0.88% on the NSE as of 03:12 PM, reflecting normal market fluctuations following the product launch announcement.
19
